Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Penile cancer

Oncology and palliative care · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Haemorrhage, infection or urinary obstruction

A neglected fungating tumour can bleed, become infected, retain urine or cause systemic sepsis.

Action: Stabilise bleeding and infection, provide analgesia and urinary drainage by an oncologically safe route with urology, and involve the specialist penile cancer centre urgently rather than performing unplanned local excision.

Synopsis

Recognise persistent penile lesions, obtain histology before destructive treatment, preserve organ and function where oncologically safe and stage inguinal nodes actively because nodal burden determines prognosis.

  • Persistent surface lesion is a pivotal clue in Penile cancer: Ulcer, plaque, nodule, warty growth, colour change or induration is suspicious when persistent or progressive.
  • Immediate priority in unstable Penile cancer: Stabilise bleeding and infection, provide analgesia and urinary drainage by an oncologically safe route with urology, and involve the specialist penile cancer centre urgently rather than performing unplanned local excision.
  • Clinical examination and photography with consent is used early to map lesion site, size, surface, shaft involvement and both groins before biopsy. Record foreskin, glans, corporal and urethral features and node size or mobility; sensitive consent and chaperoning support accurate follow-up.
  • Incisional, punch or excisional biopsy refines the next decision because choose a representative edge and adequate depth; avoid destructive laser or topical therapy without histology when invasion is possible.
  • Confirm before destructive treatment: Examine and document the entire penis and both groins, address phimosis enough to visualise the lesion and make an urgent specialist referral.
  • Preserve organ where safe: For superficial invasive disease, consider wide local excision, glans resurfacing, glansectomy or radiotherapy through an experienced organ-preserving service.
  • A major avoidable harm is inguinal and pelvic nodal metastasis; Nodal burden is the dominant prognostic factor and may remain curable when identified and resected before bulky fixation.
  • A common diagnostic trap is inflammatory balanitis: Candidal, irritant or plasma-cell inflammation can cause erythema and soreness, but persistence after appropriate care requires biopsy.

Key red flags

A painless ulcer, nodule, induration, warty growth or bleeding lesion persists on glans, prepuce or shaft.

Phimosis conceals discharge, odour, bleeding or a palpable subpreputial mass.

A lesion fails to resolve after a short appropriate treatment for presumed infection or dermatitis.

Palpable inguinal nodes persist after treatment of infection or are hard, fixed or enlarging.

Urinary obstruction, severe pain, haemorrhage, cellulitis or sepsis accompanies an advanced penile lesion.

Fungating emergency

Major bleeding, sepsis or urinary obstruction from advanced disease requires acute stabilisation and specialist transfer.

Investigation priorities

01
Clinical examination and photography with consentFirst step

Map lesion site, size, surface, shaft involvement and both groins before biopsy.

Management branches

BiopsyConfirm before destructive treatment

A persistent penile lesion is suspicious for intraepithelial or invasive cancer.

  1. Examine and document the entire penis and both groins, address phimosis enough to visualise the lesion and make an urgent specialist referral.
  2. Obtain representative incisional, punch or excisional biopsy with adequate depth before topical, laser or major surgery.
  3. Report subtype, grade, depth, lymphovascular or perineural invasion, HPV association and margin through expert pathology review.

Key medicines

Imiquimod 5% cream for penile intraepithelial neoplasiaApply a thin layer to the affected area three times weekly at night, leave for about 6–10 hours and wash off, commonly for up to 12 weeks under specialist supervision with response checks.Do not use for unbiopsied possible invasion; expect inflammation, pause or reduce for severe ulceration, and re-biopsy persistent or recurrent disease rather than repeating indefinitely.
Topical fluorouracil for penile intraepithelial neoplasiaA specialist regimen commonly applies fluorouracil 5% cream thinly once or twice daily for 4–6 weeks, with exact frequency adjusted to local reaction and product guidance.Avoid on invasive or unconfirmed lesions, counsel about marked local inflammation and safe handling, and arrange biopsy of incomplete response.
Open full textbook →Answer 2 questions
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • European Association of Urology penile cancer guidelineCurrent professional guidance used in UK specialist practice for penile cancer.
  • British Association of Urological Surgeons penile cancer informationUK pathway context and patient-centred effects of penile cancer treatment.
  • Royal College of Pathologists cancer datasetsUK pathology sampling, staging, margin and molecular reporting standards.
  • BNF imiquimod, fluorouracil, paclitaxel, ifosfamide and cisplatinUK prescribing, contraindication and monitoring information for imiquimod, fluorouracil, paclitaxel, ifosfamide and cisplatin.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom